Compare Crispr Therapeutics AG (CRSP) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Taskus Inc — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Taskus Inc trades at $8.14 (market cap $723.41M). The key difference: Crispr Therapeutics AG is far larger — about 6.7× Taskus Inc's market cap, and Taskus Inc is more actively traded (201,303 versus 2,861,747). Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Taskus Inc for 34 Days on average.
| CRSP | TASK | |
|---|---|---|
Market Cap | $4.88B | $723.41M |
Volume | 2,861,747 | 201,303 |
Sector | Health | Technology |
52-Week High | $74.92 | $14.69 |
52-Week Low | $44.34 | $4.57 |
Typical Hold Time | 77 Days | 34 Days |
Enterprise Value | $3.30B | $1.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
TaskUs (TASK) trades at $8.01, up 1.52% today, with a bearish technical signal but strong fundamentals. The company reported Q2 2026 revenue of $308.9 million, beating estimates, with net income margin improving to 8.75% in 2025. Valuation ratios appear attractive, with a P/E of 6.8 and P/S of 0.6, while analyst consensus is a Buy with a $9.33 price target. Recent news highlights AI services growth offsetting declines in other segments.
The outlook is mixed; low valuations and AI-driven revenue growth present upside, but technical bearishness and margin pressures from labor costs pose risks. Investors should weigh fundamental strength against near-term price volatility and competitive challenges in the digital services space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
